References
- Papers of special note have been highlighted as
- • of interest
- •• of considerable interest
- Vl F, Mh F, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245–254.
- Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236.
•• - cornerstone post-stroke guidelines.
- Hemphill JC 3rd, Sm G, Cs A, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: a Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032–2060.
- Pinto A, Di Raimondo D, Tuttolomondo A, et al. Antiplatelets in stroke prevention. Curr Vasc Pharmacol. 2013;11(14):803–811.
- Iannopollo G, Rm G, De Ferrari GM, et al. Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. Ther Clin Risk Manag. 2014;10:321–329.
- Hashemzadeh M, Arreguin JM, Roberts T, et al. A novel inhibitor of protease-activated receptor 1: a review of chemical structure and mode of action. Rev Cardiovasc Med. 2015;16(1):68–73..
•• - excellent general review on vorapaxar pharmacology.
- Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20–33.
- Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–1413.
•• - main positive vorapaxar trial.
- NDA 294-886. Cross-discipline Team Leader review on Vorapaxar. April 18th, 2014. [ cited 2015 May 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000SumR.pdf
•• - comprehensive unbiased review of vorapaxar and stroke.
- Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44(3):691–698.
- Lee M, Saver JL, Hong K-S, et al. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists. Stroke. 2012;43(12):3189–3195.
- Bonaca MP, Scirica BM, Braunwald E, et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014;64(22):2318–2326.
- NDA 294-886. Medical reviews on Vorapaxar. June 18th, 2014. cited 2015 May 15. Available from www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000MedR.pdf.
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med. 2007;357(20):2001–2201.
- US Food and Drug Administration. Cardiovascular and Renal Drug Advisory Committee Briefing Document: prasugrel for ACS. Silver Spring (MD): Food and Drug Administration; 2009. [ cited 2015 Jul 11]. Available from: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf.
- Serebruany VL. Redesigning TRACER after TRITON. Intern J Cardiol. 2015;197:44–47.
• - explanation of overtreatment in vorapaxar trials.
- Ramachandran R. Developing PAR1 antagonists: minding the endothelial gap. Discov Med. 2012;13(73):425–431.
- Magnani G, Bonaca MP, Braunwald E, et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015;4(3):e001505.
- Hart RG, Halperin JL, Weitz JI. Vorapaxar, combination antiplatelet therapy, and stroke. J Am Coll Cardiol. 2014;64(22):2327–2329.